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ABSTRACT: Clustering of inhibitory c-aminobutyric acidA
(GABAA) and glycine receptors at synapses is thought to
involve key interactions between the receptors, a
‘‘scaffolding’’ protein known as gephyrin and the
RhoGEF collybistin. We report the identification of a
balanced chromosomal translocation in a female patient
presenting with a disturbed sleep-wake cycle, late-onset
epileptic seizures, increased anxiety, aggressive behavior,
and mental retardation, but not hyperekplexia. Fine
mapping of the breakpoint indicates disruption of the
collybistin gene (ARHGEF9) on chromosome Xq11,
while the other breakpoint lies in a region of 18q11 that
lacks any known or predicted genes. We show that
defective collybistin transcripts are synthesized and exons
7–10 are replaced by cryptic exons from chromosomes X
and 18. These mRNAs no longer encode the pleckstrin
homology (PH) domain of collybistin, which we now
show binds phosphatidylinositol-3-phosphate (PI3P/
PtdIns-3-P), a phosphoinositide with an emerging role
in membrane trafficking and signal transduction, rather
than phosphatidylinositol 3,4,5-trisphosphate (PIP3/
PtdIns-3,4,5-P) as previously suggested in the ‘‘mem-
brane activation model’’ of gephyrin clustering. Consis-
tent with this finding, expression of truncated collybistin
proteins in cultured neurons interferes with synaptic
localization of endogenous gephyrin and GABAA recep-
tors. These results suggest that collybistin has a key role
in membrane trafficking of gephyrin and selected
GABAA receptor subtypes involved in epilepsy, anxiety,
aggression, insomnia, and learning and memory.
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Introduction
Inhibitory g-aminobutyric acidA (GABAA) and glycine recep-
tors are heteropentameric ligand-gated chloride ion channels that
usually facilitate fast-response, inhibitory neurotransmission in
the human brain and spinal cord. Defects in mammalian
glycinergic neurotransmission result in a complex motor disorder
characterized by neonatal hypertonia and an exaggerated startle
reflex, known as hyperekplexia. In humans, missense and
nonsense mutations in the GlyR a1 gene (GLRA1; MIM]
138491) and the glycine transporter GlyT2 (SLC6A5; MIM]
604159) are the major causes of this disorder [Shiang et al., 1993;
Rees et al., 2006]. By contrast, mutations in GABAA receptor
(GABAAR) subunit genes are associated with rare familial forms of
idiopathic generalized epilepsy (IGE), such as childhood absence
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epilepsy (CAE), generalized epilepsy with generalized seizures plus
(GEFS1), and juvenile myoclonic epilepsy (JME). However, despite
the multiple subunits available for assembly of heteropentameric
receptors (a1-6, b1-3, g1-3, d, e, y, and p) to date, surprisingly few
mutations linked to IGEs have been identified in GABAAR subunit
genes. Missense or frameshift mutations in the GABAAR a1 subunit
gene (GABRA1; MIM] 137160) are associated with JME [Cossette
et al., 2002] and CAE [Maljevic et al., 2006]. By contrast, missense,
splice-site mutations, and deletions in GABRG2 (MIM] 137164),
encoding the g2 subunit, were found in families with GEFS1 and
CAE with febrile seizures [Baulac et al., 2001; Wallace et al., 2001;
Harkin et al., 2002; Kananura et al., 2002; Audenaert et al., 2006].
Consistent with this finding, g2 subunit missense mutations appear
to cause temperature-dependent GABAAR trafficking deficiencies
[Kang et al., 2006]. The limited contribution of GABAAR subunit
gene mutations to epilepsy may reflect the different spatial and
temporal expression patterns and biological roles of specific
GABAAR subtypes, functional redundancy via gene compensation,
and the considerable genetic heterogeneity found in IGEs [Heron
et al., 2007]. However, we consider that aberrant trafficking or
defective synaptic localization of GlyR and/or GABAARs could also
have a significant impact in both hyperekplexia and epilepsy.
Several lines of evidence suggest that synaptic localization of GlyRs
and some GABAARs is critically dependent on interaction of these
receptors with a ‘‘scaffolding’’ protein known as gephyrin, which is
in turn targeted to synapses by collybistin/hPEM2 [Kins et al., 2000;
Kneussel and Betz, 2000; Harvey et al., 2004], a GDP-GTP exchange
factor [Xiang et al., 2006] for the GTPase Cdc42. We report here a
balanced chromosomal translocation affecting the collybistin gene
(ARHGEF9; MIM] 300429) in a patient with a disturbed sleep-
wake cycle, epilepsy, increased anxiety, aggressive behavior, and
mental retardation, but not hyperekplexia, suggesting a broad
disruption of several GABAergic but not glycinergic circuits.
Materials and Methods
Mapping the Balanced Chromosomal Translocation in
ARHGEF9
Patient and control samples were obtained with informed
consent. Karyotype analysis was performed using standard high-
resolution techniques. For breakpoint mapping, YACs, BACs, and
PACs were prepared by standard techniques, labeled with
appropriately coupled dUTPs by nick translation or directly
labeled by Degenerate Oligonucleotide Primer PCR (DOP-PCR),
and used as probes for fluorescence in situ hybridization (FISH) as
described [Wirth et al., 1999]. For Southern blotting, PCR-
amplified DNA probes were labeled with a[32P]dCTP using
random hexamers and hybridization buffer containing 10% (w/v)
PEG 6000, 0.125M Na3PO4, 0.25M NaCl, 0.001M EDTA, 7%
(w/v) SDS, supplemented with salmon or herring sperm DNA.
The probe used for breakpoint identification was amplified with
primers ChrX-180019 and ChrX-181201. Suppression PCR on
RsaI-digested patient DNA was performed as described [Siebert
et al., 1995] with adapter primer AP1 and chromosome X
sequence-specific primer ChrX-180618, followed by a nested PCR
with adapter primer AP2 and ChrX-180659. For breakpoint
analysis of derivative chromosome 18, genomic patient DNA was
amplified with primers Chr18-85079F1 and ChrX-181201.
Sequences of all primers used in this study are provided
in Supplementary Table S1 (available online at http://www.
interscience.wiley.com/jpages/1059-7794/suppmat).
RT-PCR and 30 RACE Analysis of ARHGEF9 Transcripts
Total RNA was isolated from patient and control lymphoblastoid
cell line using Trizol (Invitrogen, Carlsbad, CA) according to the
manufacturer’s recommendations. A total of 5mg of RNA were used
for reverse transcription with Superscript III (Invitrogen) in the
presence of RNAguard (GE Healthcare, Chalfont, UK), using either
oligonucleotide dT or random hexamers for priming. 30 RACE was
performed using primers hPEM2-Ex5 and hPEM2-Ex6 using the
GeneRacer kit (Invitrogen) according to the manufacturer’s direc-
tions. Full-length cDNAs were amplified using Pfx proofreading DNA
polymerase (Invitrogen), using primers based on the human
ARHGEF9 cDNA sequence (NM_015185.2) and/or 30 RACE
fragments, cloned into the BamHI and EcoRI sites of pRK5-myc
and fully sequenced. All PCR products and cDNA clones were
sequenced using BigDye terminator mix (Applied Biosystems,
Warrington, UK) using an ABI 3100 (Applied Biosystems,
Warrington, United Kingdom).
Gephyrin Clustering Assays in Cellular Models
Gephyrin clustering assays in cellular models were performed as
previously described [Harvey et al., 2004]. HEK293 cells were
cotransfected with pRK5myc-hPEM2 constructs at a 1:1 ratio with
enhanced green fluorescent protein (pEGFP)-gephyrin using
Effectine (Qiagen, Crawley, UK) and after 24 hrs in culture were
fixed in 4% (w/v) PFA in PBS and immunostained with a 1:1,000
dilution of mouse anti-myc antibody (R950-25; Invitrogen),
detected using a 1:500 dilution of AlexaFluor 488 goat anti-mouse
secondary antibody (Invitrogen) and counterstained with a
1:10,000 dilution of ToPro-3 (T3605; Invitrogen).
Lipid Protein Overlay Assays
Lipid protein overlay assays were performed according to the
method of Dowler et al. [2000]. Phosphoinositides (Cell Signals,
Columbus, OH) were dissolved in methanol/chloroform/water
(2:1:0.8) to give concentrations in the range of 100–1.6 pmol/ml and
spotted onto nitrocellulose filters (GE Healthcare, Chalfont, UK)
and dried for 1 hr at room temperature (RT). Membranes were then
blocked in Tris-buffered saline Tween-20 (TBST) (50mM Tris-HCl
pH 7.4, 150mM NaCl, and 0.1% (v/v) Tween-20) containing 5%
(w/v) skim milk powder for 1 hr at RT. Glutathione-S-transferase
(GST)-tagged hPEM2 or centaurin a1 were isolated from E. coli
BL21 (DE3) from corresponding constructs cloned in pGEX4T.
GST-hPEM2 or GST-centaurin a1 (2mg/ml) was then added to the
blocking solution and incubated overnight at 41C. The membranes
were then washed three times with TBST. Bound protein was
detected by immunoblotting with a 1:2,000 dilution of an anti-GST
goat polyclonal antibody (27-4577-01; GE Healthcare) for 1 hr,
three washes in TBST, and detected with a 1:2,500 dilution of
horseradish peroxidase (HRP)-conjugated anti-goat immunoglo-
bulin G (IgG) (A5420; Sigma-Aldrich, Gillingham, UK) for 1 hr,
followed by three washes in TBST. HRP activity was detected using
enhanced chemiluminescence reagent (ECL; GE Healthcare) and by
exposing to X-ray film for 1 to 5min.
Neuronal Cell Culture, Transfection, and Quantification of
Gephyrin/GABAAR Clustering
Cultures of cortical neurons were generated from embryonic
day 14.5 (E14.5) mouse embryos, as described previously [Essrich
et al., 1998; Harvey et al., 2004]. They were transfected at 18 days
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in vitro (DIV) and processed for immunofluorescence analysis
under permeabilized conditions 2 days later. The following
primary antibodies were used: guinea pig anti-g2 (1:1,500; a gift
from J.M. Fritschy, University of Zurich, Switzerland), rabbit anti-
myc (1:1,000, clone 9E10, generated in-house), and anti-gephyrin
monoclonal antibody 7a (mAb7a) (1:1,000; a gift from H. Betz,
Max-Planck-Institut fu¨r Hirnforschung, Frankfurt, Germany).
Antibodies were detected with 1:500 dilutions of Alexa Fluor 488-
conjugated goat anti-mouse, Cy3-conjugated donkey anti-guinea
pig (Jackson ImmunoResearch, West Grove, PA), and Alexa Fluor
647 goat anti-rabbit (Invitrogen). Fluorescent images were
captured from a Zeiss Axiophot 2 microscope (Carl Zeiss
MicroImaging, Thornwood, NY) equipped with a 40 1.3
numerical aperture objective and an ORCA-100 video camera
(Hamamatsu Photonics, Bridgewater, NJ) linked to an OpenLab
imaging system (Improvision, Lexington, MA). Images were
adjusted for contrast using OpenLab or FlowView software,
respectively, and assembled into figure palettes using Adobe
PhotoShop (Adobe Systems, San Jose, CA). For semiquantitative
analyses of labeled GABAAR and gephyrin clusters, digitized
microscopic images were recorded, and two dendritic segments of
length 40 mm each were selected from each transfected neuron
from three or more independent experiments [Harvey et al.,
2004]. Immunoreactive puncta were automatically selected using
OpenLab, applying a fluorescence intensity threshold correspond-
ing to twice the diffuse fluorescence measured on the shaft of the
same dendrite and a target size range of 0.2 to 2 mm in diameter.
Statistical comparisons were performed using Student’s t-test.
Results
The proband was the first child of healthy unrelated parents
delivered at term via Cesarean section due to obstetric problems.
Birth weight (3,140 g, 50th percentile) and length (50 cm, 50th
percentile) were normal. At the age of 7 months, generalized
hypotonia and psychomotor developmental arrest were noted.
Cerebral nuclear magnetic resonance (NMR) results were normal
and screening for inborn errors of metabolism excluded amino
acid pathologies or organic acidurias. At the age of 1 year and 9
months her weight was 9.6 kg (5th percentile), height 75.5 cm
(o5th percentile), and head circumference 46.9 cm (10th
percentile). She was hypotonic and unable to sit without support.
The EEG at this stage and 2 years later showed relatively slow
rhythm and partial disorganization of basic activity. At the age of 6
years, her weight was 14 kg (o3rd percentile), height 98 cm
(o3rd percentile), and head circumference 50 cm (25th–50th
Figure 1. Mapping a balanced chromosomal translocation in ARHGEF9. A: Patient photographs showing dysmorphic features (long and
narrow face, irregular teeth, and micrognathia). B: Ideograms depicting the translocated chromosomes and their normal homologs. C: FISH
analysis with chromosome 18 BAC clones with signals proximal and distal to the breakpoint and chromosome X BAC clone RP11-943J20, which
spans the X breakpoint. D: Southern blot analysis of the breakpoint within ARHGEF9 intron 6. SacI, XbaI, and RsaI digests revealed patient-
specific bands of approximately 6, 11, 3, and 1.3 kb, which are absent in the control DNA. E: Sequence of the junction fragments and the
respective genomic regions of the normal homologs. The four nucleotides identical in the breakpoint region and lost during rearrangement from
one of the derivative chromosomes are boxed. F: Schematic diagram depicting ARHGEF9 with the location of the chromosome breakpoint
(arrow) as determined by FISH, breakpoint cloning, and RT-PCR experiments. The breakpoint-spanning BAC RP11-943J20 is shown below the
gene. G: ARHGEF9 transcript analysis in patient and control cell line RNAs. For the patient cell line, transcripts could be detected from
derivative chromosome 18 (e.g., exons 4–6 and 5–6). However, no products could be obtained using primers spanning the breakpoint (exons 5–7)
and within exons located proximal to the breakpoint (exons 8–10) on the derivative X chromosome. Specific bands of the expected size are
present in all RT-PCRs from the control.
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Figure 2. Rapid amplification of cDNA ends reveals defective ARHGEF9 transcripts resulting in a loss of the collybistin PH domain and
C-terminus. A: Analysis of collybistin transcripts using 30 RACE demonstrates the loss of exons 7–10 from collybistin transcripts, which are
replaced by cryptic exons from chromosomes X and 18. B: Splicing of these cryptic exons results in the loss of the collybistin PH domain and
C-terminus. C: Using immobilized phosphoinositides and purified GST-collybistin we found that the PH domain is functional, binding PI3P/PtdIns-
3-P (phosphatidylinositol-3-phosphate) rather than PIP3/PtdIns-3,4,5-P (phosphatidylinositol 3,4,5-trisphosphate) as predicted by the ‘‘membrane
activation model’’ of gephyrin clustering [Kneussel and Betz, 2000]. Controls using centaurin a1 verified that these overlay assays were capable
of detecting binding to PIP2 and PIP3.
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percentile). Dysmorphic features included a long and narrow face,
high narrow palate, hypertrophy of the alveolar ridge, irregular
teeth, and micrognathia (Fig. 1A). Although the patient was able
to walk autonomously, she was hyperactive and had no verbal
communication. At the age of 7 years, she developed generalized
tonic-clonic seizures, which occurred during the initial sleeping
phase, although MRI scans were normal. Since the age of 8 years,
the patient has suffered from frequent mood changes and a
disturbed sleep-wake rhythm. She dislikes being touched by others
or the proximity of other children. In situations where she
becomes agitated, which can be triggered by changes in her
environment, she shows self-injurious behaviors such as hand
biting and punching her head. Likewise, she shows injurious
behaviors against others. At the age of 12 years the patient was
profoundly mentally retarded with a psychoeducational level of
7–12 months old. At the age of 14 years the parents noticed
obstructive sleep apnea, which was treated by surgery. At a recent
examination, at the age of 15 years her weight was 27 kg (oo3rd
percentile), her height 140 cm (oo3rd percentile), and her
occipital-frontal circumference was 53.5 cm (oo3rd percentile).
She had few words or social responses and a reduced sensitivity to
thermal pain was noted. Seizures, mood, and behavior problems
improved through treatment with the benzodiazepine clonaze-
pam, the GABA transaminase inhibitor valproic acid, and the
atypical antipsychotic risperidone.
Karyotyping in this individual revealed a de novo balanced
chromosomal translocation 46,X,t(X;18) (q11.1;q11.21), depicted
in Figure 1B. Breakpoints were mapped by sequential FISH of
genomic clones from both chromosomes 18 and X. On
chromosome 18, the breakpoint lies within the genomic
region of clones RP11-29E21 and RP11-885L22 (chr18:
24,344,568–24,564,620) (Fig. 1C, right panel), which does not
contain any known or predicted genes. However, on chromosome
X, we noted that BAC clone RP11-943J20, containing ARHGEF9,
spanned the breakpoint (Fig. 1C, left panel). The breakpoint was
localized by Southern blot analysis of patient DNA, which revealed
aberrant patient-specific DNA fragments in several digests (Fig.
1D). Subsequent cloning and sequence analysis of the junctional
fragment revealed that the breakpoint lies between exons 6 and 7
of ARHGEF9 (Fig. 1E and F). We ruled out a deletion at the
breakpoint on derivative chromosome 18 by sequencing the PCR-
amplified breakpoint region (Fig. 1F), indicating that the
translocation is balanced. Additional aberrations unrelated to this
breakpoint were also excluded by array comparative genomic
hybridization (CGH) analysis (Supplementary Fig. S1).
Since in balanced X-autosome translocations, the normal X
chromosome is often preferentially inactivated [Kalz-Fu¨ller et al.,
1999], RNA derived from an immortalized patient leukocyte cell
line was tested for ARHGEF9 transcripts. RT-PCR amplifications
with primers located in ARHGEF9 exons 5 and 7, which flank the
breakpoint and in exons 8 and 10, which are both located
proximal to the breakpoint on the derivative X chromosome,
indicated that full-length ARHGEF9 transcripts are absent in the
patient, whereas products of the expected size were easily
amplifiable from control RNA (Fig. 1G). This analysis verified
that the chromosomal rearrangement has led to inactivation of the
Figure 3. Cellular models of gephyrin clustering demonstrate that hPEM2-18 and hPEM2-X colocalize with gephyrin, but do not direct the
formation of submembrane microaggregates. A: Western blots of myc-tagged hPEM2 constructs expressed in HEK293 cells indicate that the
aberrant myc-hPEM2-18 and myc-hPEM2-X proteins are stable and expressed at equivalent levels to myc-hPEM2SH31 and myc-hPEM2SH3–
when compared to loading control (a-tubulin). B: Schematic diagram showing the domains specified by the different hPEM2 constructs. C–F:
Coexpression of myc-tagged hPEM2 proteins with EGFP-gephyrin in HEK293 cells costained with a nuclear marker (ToPro3). As expected, myc-
hPEM2SH31 normally colocalizes with gephyrin in large intracellular aggregates (C), while myc-hPEM2SH3– directs EGFP-gephyrin to
submembrane clusters (D). Although they lack the regulatory SH3 domain, myc-hPEM2-18 (E) and myc-hPEM2-X (F) proteins colocalize with
gephyrin, but do not direct the formation of submembrane microaggregates.
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normal X chromosome and that ARHGEF9 is subject to X
inactivation. However, PCR products corresponding to exons 4–6
and exons 5–6, which in the patient are present on the derivative
chromosome 18, indicated that truncated ARHGEF9 transcripts
are produced. Further analysis using 30 RACE revealed two classes
of ARHGEF9 transcript containing exons 1–6 followed by cryptic
exons derived from intronic or intergenic sequences on chromo-
somes X and 18, each containing a consensus polyadenylation
signal (Fig. 2A; Supplementary Fig. S2). As a result, patient-specific
truncated ARHGEF9 mRNAs are generated, producing two classes
of truncated proteins designated hPEM-X and hPEM-18. Interest-
ingly, splicing of these cryptic exons results in the loss of the
collybistin pleckstrin homology (PH) domain and C-terminus.
Using immobilized phosphoinositides and purified GST-collybistin
in overlay assays [Dowler et al., 2000], we determined that the PH
domain is required for collybistin function (Fig. 2C) since it binds
the phosphoinositide PI3P (PtdIns-3-P/phosphatidylinositol-3-phos-
phate), a phosphoinositide with an emerging role in membrane
trafficking and signal transduction [Falasca and Maffucci, 2006]. This
result was somewhat unexpected, since collybistin has previously
been suggested to bind phosphatidylinositol 3,4,5-trisphosphate
(PIP3/PtdIns-3,4,5-P) in the ‘‘membrane activation model’’ of
gephyrin clustering [Kneussel and Betz, 2000]. However, controls
using centaurin a1, a known PIP2 and PIP3 binding protein
[Venkateswarlu et al., 2004], verified that our overlay assays were
capable of detecting binding to these phosphoinositides (Fig. 2C).
Western blot analysis of myc-tagged hPEM constructs expressed
in HEK293 cells indicates that the aberrant hPEM2-18 and
hPEM2-X proteins are stable and expressed at levels equivalent to
hPEM2SH31 and hPEM2SH3– when normalized to endogenous a-
tubulin (Fig. 3A and B). Coexpression of myc-tagged hPEM2
proteins with EGFP-gephyrin in HEK293 cells revealed that, as
expected [Kins et al., 2000; Harvey et al., 2004], variants
containing the regulatory SH3 domain (hPEM2SH31) colocalize
with EGFP-gephyrin in large intracellular aggregates (Fig. 3C),
while hPEM2SH3–, lacking the SH3 domain, directs EGFP-
gephyrin to submembrane clusters (Fig. 3D). However, although
hPEM2-18 (Fig. 3E) and hPEM2-X (Fig. 3F) lack the SH3
domain, these proteins colocalize with EGFP-gephyrin and do not
direct the formation of submembrane microaggregates. To
examine the effects of these proteins on neuronal gephyrin and
GABAAR g2 subunit clustering, we expressed these hPEM2
constructs in primary cultures of mouse cortical neurons.
Punctate immunofluorescent staining for these proteins is
representative of postsynaptic GABAAR and gephyrin clusters,
respectively. Overexpression of myc-hPEM2SH31 or myc-
Figure 4. Overexpression of truncated collybistin mutants in neurons results in loss of gephyrin and GABAAR clusters. Triple staining of
neurons transfected with either myc-hPEM2SH31 (A,B), myc-hPEM2SH3– (C,D) or mutant constructs myc-hPEM2-X (E,F) and myc-hPEM2-18 (G,H)
with antibodies against the GABAA receptor g2 subunit (red), gephyrin (green), and myc-tag (blue). Note that myc-hPEM2SH31 or myc-
hPEM2SH3– do not interfere with the colocalization of gephyrin and GABAA receptors in synaptic clusters (A–D). Quantitative analysis shows
that hPEM2SH31 or myc-hPEM2SH3– do not influence gephyrin puncta number (I) although deletion of the regulatory SH3 domain influences
puncta size (J). In neurons expressing myc-hPEM2-X (E,F) and myc-hPEM2-18 (G,H), gephyrin and GABAA receptor immunoreactivity is
significantly reduced. Note that gephyrin and GABAA receptor clustering in neighboring neurons that do not express the myc-hPEM mutants is
unaffected (E–H). Quantitative analysis of gephyrin immunofluorescence (I,J) indicates a statistically-significant loss of gephyrin clusters and a
reduction in size of remaining clusters. Po0.001, Student’s t-test, n5 17–28 cells per construct.
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hPEM2SH3– did not interfere with the colocalization of gephyrin
or GABAARs in synaptic clusters (Fig. 4A–D). Quantitative
analysis revealed that neither hPEM2SH31 nor myc-hPEM2SH3–
influence gephyrin puncta number (Fig. 4I) although deletion of
the regulatory SH3 domain caused a modest increase in puncta
size (Fig. 4J). By contrast, in neurons expressing myc-hPEM2-X
(Fig. 4E, F) and myc-hPEM2-18 (Fig. 4 G and H), punctuate
gephyrin and GABAAR immunoreactivity was significantly
reduced, suggesting that these truncated proteins can act in a
dominant-negative manner and interfere with the accumulation
of endogenous gephyrin and GABAARs at synaptic sites.
Quantitative analyses of the punctuate gephyrin immunofluores-
cence (Fig. 4I and J) confirmed that the number of gephyrin
clusters was dramatically reduced, along with a significant
reduction in size of the few remaining clusters.
Discussion
We describe a balanced chromosomal translocation truncating
ARHGEF9 that results in a range of clinical symptoms including a
disturbed sleep-wake cycle, late-onset epileptic seizures, increased
anxiety, aggressive behavior, and mental retardation. The translo-
cation results in the production of functionally defective
collybistin isoforms, lacking the PH domain and C-terminus.
Loss of the collybistin PH domain is predicted to abolish PI3P
binding, but does not affect interactions with gephyrin via the
RhoGEF domain. We demonstrate that these truncated collybistin
isoforms cause loss of synaptic gephyrin and GABAARs via a
dominant-negative mechanism, suggesting that the loss of specific
GABAAR subtypes may underlie the symptoms observed in this
individual. For example, mutations in human GABAAR a1 and g2
subunit genes are associated with various types of IGEs [Baulac
et al., 2001; Wallace et al., 2001; Cossette et al., 2002; Harkin et al.,
2002; Kananura et al., 2002; Audenaert et al., 2006; Maljevic et al.,
2006], while a mutation in the GABAAR b3 subunit gene
(GABRB3) was reported in an individual with chronic insomnia
[Buhr et al., 2002]. Homozygous GABAAR g2 subunit knockout
mice show retarded growth, sensorimotor dysfunction, a reduced
life-span, and epileptic seizures [Gu¨nther et al., 1995; Essrich et al.,
1998; Schweizer et al., 2003], while mice heterozygous for g2
exhibit enhanced anxiety and a memory bias for threat cues,
resulting in heightened sensitivity to negative associations
[Crestani et al., 1999]. This may be linked to GABAARs containing
the a2 subunit, which are responsible for the anxiolytic effects of
benzodiazepines [Lo¨w et al., 2000]. By contrast, a loss of
GABAARs containing the a3 subunit induces a hyperdopaminer-
gic phenotype involving a deficit in sensorimotor gating [Yee
et al., 2005], a common feature among psychiatric conditions,
including schizophrenia. In this regard, it is noteworthy that the
individual in this study responded to the use of antipsychotics and
mood stabilizing drugs.
In conclusion, it is now apparent that different mutations in
ARHGEF9 give rise to a diverse range of clinical symptoms
(Table 1). The missense mutation p.G55A in the SH3 domain
gives rise to a severe phenotype encompassing hyperekplexia,
drug-resistant seizures, and premature death, caused by somatic
and dendritic trapping of gephyrin and receptors by collybistin
Table 1. Phenotypic Comparison of Human ARHGEF9 Mutations
Clinical features Harvey et al. [2004] Marco et al. [2008] Present study
ARHGEF9
mutation and
karyotype
p.G55A; 46,XY 46,X,inv(X)(q11.1q27.3) 46,X,t(X;18)(q11.1;q11.21)
Sex Male Female Female
Age of
examination
Died at age 4 years 4 months 15 years 15 years
Head
circumference
Not determined Within normal range 3rd percentile
Body height Not determined Within normal range Short stature
Brain MRI Significant brain atrophy in the
cerebral cortex and cerebellar
vermis
No abnormalities reported No abnormalities reported
Mental
retardation /
developmental
delay
Severe Mild to moderate Severe
Epilepsy EEG revealed left temporal spike
waves at 18 months, frequent
long-lasting seizures
Not reported First seizures at age 7 years, generalized
tonic-clonic seizures
Hyperekplexia Yes, muscle stiffness at birth
and seizures provoked by
tactile stimulation
Not reported Not reported
Hyperarousal
to noise
Not reported Yes Not reported
Behavior Arrest and decline of
psychomotor development
Autonomic hyperarousal to noise
and social situations, hyperactivity,
impulsivity, shyness, motor
incoordination
Aggression, autoaggression, hyperactivity,
frequent mood changes, disturbed sleep-wake
rhythm, obstructive sleep apnea
Facial
dysmorphisms
Not reported Not reported Long and narrow face, high narrow palate,
hypertrophy of the alveolar ridge, irregular teeth,
micrognathia
Other features Not reported Not reported Insensitivity to thermal pain
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aggregates [Harvey et al., 2004]. By contrast, a female patient with
an X chromosome inversion affecting one copy of ARHGEF9, but
with low expression from the unaffected ARHGEF9 copy, suffered
from mild mental retardation and sensory hyperarousal, but not
seizures or hyperekplexia [Marco et al., 2008]. Thus, compara-
tively severe phenotypes are observed when dominant-negative
forms of hPEM2 are expressed, as previously shown for the
p.G55A mutation [Harvey et al., 2004] and the translocation
reported here, which sequester gephyrin and GABAARs from
synaptic sites. Collybistin may also be dispensable for GlyR
clustering, since hyperekplexia does not appear to be a common
feature in humans with ARHGEF9 rearrangements, nor collybis-
tin knockout mice [Papadopoulos et al., 2007], which show
increased levels of anxiety and impaired spatial learning due to a
selective loss of GABAARs in the hippocampus and the basolateral
amygdala. This suggests that additional RhoGEFs involved in
inhibitory receptor clustering remain to be identified.
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